Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of AK104 (Cadonilimab) Combined with Chemotherapy for Recurrent or Metastatic Small Cell Neuroendocrine Carcinoma of the Cervix: a Single-Arm, Open-Label, Multicenter Clinical Study

NCT06810895 is registered in ClinicalTrials.gov with Ding Ma as lead sponsor.

NCT NCT06810895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06810895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of AK104 (Cadonilimab) Combined with Chemotherapy for Recurrent or Metastatic Small Cell Neuroendocrine Carcinoma of the Cervix: a Single-Arm, Open-Label, Multicenter Clinical Study
Lead sponsor
Ding Ma
Phase
Observational
Overall status
Enrolling by invitation
Start date
February 1, 2025
Completion date
December 1, 2032
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cadonilimab, cervix cancer, small cell neuroendocrine carcinoma of the cervix